Redesigning cardiometabolic patient care

• Adopting high intensity titration models like the one validated in the STRONG-HF trial can significantly reduce mortality and rehospitalization rates through precise biomarker guided protocols
• Bridging the persistent evidence-practice gap in heart failure requires the structured application of implementation science to secure the vulnerable post discharge transition
• Successful institutional transformation is accelerated by collaborating with an industry partner that provides the specialized tools and change management frameworks needed to redesign complex patient journeys

The transition from clinical breakthrough to routine bedside practice is rarely linear. In cardiometabolic medicine, a persistent evidence-practice gap remains one of the most significant hurdles to improving patient outcomes.¹ While large-scale clinical trials continuously redefine the gold standard of care, the systematic adoption of these findings often lags.^2,3 This delay is particularly evident in the management of heart failure, where the post-discharge period represents a critical window of vulnerability.^4-6

Bridging this gap requires a shift toward implementation science. Implementation science focuses on identifying effective strategies to integrate evidence-based interventions into routine clinical practice while accounting for organizational, behavioural and system-level barriers. Many hospitals find that a focus on structured application of implementation science strategies helps to integrate evidence-based interventions into regular clinical workflows.⁷

Our latest white paper explores how healthcare practitioners and leaders can navigate these systemic hurdles to ensure that medical breakthroughs reach the patients who need them most.

The period following a hospital discharge for acute heart failure is a critical phase for patients with high risk of mortality and hospital readmissions.⁸ The treating physicians are faced with management of a complex interplay of patient monitoring, rapid medication adjustments, management of comorbidities, and coordination across different clinical settings. 

While the clinical community recognizes the aforementioned discharge phase as vulnerable, standard protocols can lack the agility required for rapid intervention. Ultimately, despite the existence of guidelines and innovative care models, the real world optimization of therapy management during this window can remain challenging. For example, while evidence-based, structured care pathways, such as STRONG-HF and New Zealand’s Accelerated Treatment Pathway (ATP), have demonstrated meaningful improvements in both clinical and health system outcomes, their adoption in routine practice remains inconsistent.⁹

The downloadable white paper outlines the structural barriers that contribute to this vulnerability and offers insights into redesigning the patient journey to provide a more secure safety net.

The results of the STRONG-HF trial have set a new benchmark for heart failure management, demonstrating that a proactive approach can lead to a significant 34% reduction of HF readmission or all cause mortality at 180 days.^10,11 This model moves away from conventional, slower titration schedules in favor of a high-intensity strategy that optimizes treatment within weeks of discharge. A vital component of this success is the use of biomarker guided decision making (NT-proBNP levels) to monitor cardiac stress and ensure safety during rapid dose adjustments.^10,11

At the same time, translating trial results into a sustainable hospital program involves operational shifts. The full white paper teases out details of the STRONG-HF trial, along with requirements for adopting such a model; it details specific protocolized visit cadences and safety thresholds that made these clinical gains possible, offering a potential blueprint for institutions to step towards modernization. The STRONG HF strategy has subsequently informed international heart failure guidance and implementation initiatives.¹²

While the STRONG-HF trial demonstrated the clinical benefits of a high-intensity, biomarker-guided follow-up strategy after hospitalization for acute heart failure, translating this evidence into routine practice requires additional implementation efforts. Implementation support frameworks, such as Disease Management Consulting (DMC), are intended to facilitate local adoption of evidence-based care pathways and were not evaluated as part of the STRONG-HF trial.

Implementing a model as STRONG-HF is not merely a clinical challenge; it is an operational one. Healthcare institutions may benefit from collaborating with experienced implementation partners when adapting evidence-based care models to local practice. This is where working with a strategic industry partner becomes an essential collaboration, allowing physicians to focus on clinical excellence while the partner manages the operational complexities of the transformation. Rather than acting as a mere supplier, an industry partner could serve as a facilitator for change management, providing specialized tools and dedicated work bandwidth for redesigning patient journeys, aligning multidisciplinary teams, and establishing new feedback loops.

Such a partnership offers a structured framework (the so-called Disease Management Consulting (DMC)) to support hospitals through the transition. By leveraging external expertise, organizations can:

• Accelerate time to implementation
• Enhance consistency and standardization of care
• Strengthen internal capabilities through knowledge transfer
• Improve the likelihood of achieving sustainable clinical and operational outcomes ¹³

It is important to note that successful implementation requires institutional commitment, multidisciplinary coordination, adequate outpatient capacity and adaptation to local healthcare systems. In the full report, we detail how this expert-led support helps hospitals overcome the friction of institutional change, allowing physicians to focus on clinical excellence while the partner manages the operational complexities of the transformation.

Redesigning cardiometabolic care is an investment that may generate sustained clinical and operational benefits across the entire healthcare institution. By adopting a multidisciplinary, structured approach, hospitals can achieve more than just improved clinical metrics. They can build a platform for future innovation that integrates advanced diagnostics and contemporary therapies into a unified, scalable system.

The white paper provides a comprehensive look at the measurable outcomes hospitals can expect, from improved quality of life scores to enhanced operational efficiencies. We invite you to learn more about how to enact this transformation within your own institution.